The Time Has Come for Agenus to Excel. See Also: Why Evoke Pharma Traded UP Today

Agenus Has Two Separate Press Releases
In the First Press Release from Agenus:
Agenus (AGEN) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181 at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting. 

AGEN1181 - an Fc-engineered anti-CTLA-4 that has . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.